Patients were randomly assigned ( @:@ ) to receive trabectedin @ mg/m@ @-h intravenous ( i.v. ) infusion every @ weeks ( q@wk ) ( Arm A ) , or doxorubicin @ mg/m@ i.v. , q@wk , or doxorubicin @ mg/m@ i.v. plus ifosfamide ( range , @-@ g/m@ ) i.v. q@wk ( Arm B ) .